Specializes in developing genetically-targeted therapies for cardiovascular diseases, aiming to personalize treatment.
ARCA biopharma, Inc. is a clinical-stage biopharmaceutical company specializing in the development and commercialization of genetically targeted therapies for cardiovascular diseases. Established in 2004 and headquartered in Westminster, Colorado, ARCA focuses on advancing innovative treatments tailored to the genetic profiles of patients. The company's primary product candidates include Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), currently undergoing Phase IIb clinical trials for the treatment of COVID-19, and Gencaro (bucindolol hydrochloride), a beta-adrenergic receptor antagonist designed with pharmacogenetic targeting capabilities. Gencaro has completed Phase IIb trials for managing atrial fibrillation in patients with chronic heart failure.
ARCA biopharma collaborates extensively to bolster its research and development efforts. Notably, the company has partnered with LabCorp to develop a genetic test specifically for the GENETIC-AF clinical trial, enhancing patient selection criteria based on genetic markers. Additionally, ARCA maintains a research collaboration with the Colorado Prevention Center, part of the University of Colorado's Academic Research Organization, aimed at further developing and commercializing Gencaro. These strategic collaborations underscore ARCA biopharma's commitment to leveraging cutting-edge genetic insights to advance personalized therapies for cardiovascular conditions.
Formerly known for its pioneering work in cardiovascular genetic medicine, ARCA biopharma rebranded in alignment with its expanded focus on genetically targeted therapies. With a strong foundation in biopharmaceutical innovation and a dedication to improving patient outcomes through precision medicine, ARCA biopharma continues to lead the charge in transforming the treatment landscape for cardiovascular diseases.